Pro-Dex
PDEX
Market cap $129M

39.56 USD

-1.36

3.32%

At close Jun 13, 4:00 PM EDT

1 day

-3.32%

5 days

-7.91%

1 month

-6.90%

3 months

-13.44%

6 months

-19.98%

Year to date

-14.67%

1 year

101.84%

5 years

119.17%

10 years

1,642.73%

About: Pro-Dex Inc is engaged in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used in the orthopedic, thoracic, and craniomaxillofacial (CMF) markets. The company also designs and manufactures multi-axis motion control systems used in factory automation and scientific research markets. Majority of the company's revenue is derived from designing, developing, and manufacturing surgical devices for the medical device and dental industries.

Employees: 148

Healthcare Medical Instruments & Supplies

0

Funds holding %

of 7,296 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

20% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 10

6% more capital invested

Capital invested by funds: $32M [Q4 2024] → $33.9M (+$1.95M) [Q1 2025]

2% more funds holding

Funds holding: 42 [Q4 2024] → 43 (+1) [Q1 2025]

8% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 12

0.07% more ownership

Funds ownership: 20.98% [Q4 2024] → 21.05% (+0.07%) [Q1 2025]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$56

42%

upside

Avg. target

$56

42%

upside

High target

$56

42%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Ascendiant Capital

Edward Woo

42%upside

$56

Buy

Maintained

27 May 2025

See Analyst Rankings

Financial journalist opinion

Pro-Dex: Crash After Strong Earnings Leads To A Buying Opportunity

Pro-Dex, Inc. experienced a 32% stock crash despite record Q3 2025 performance, presenting a buying opportunity for risk-tolerant investors. Q3 2025 revenue grew 22% YoY, with gross profit up 45% due to favorable product mix; operating income increased 64%. PDEX's PEG ratio of 0.27x indicates undervaluation compared to sector median, despite higher valuation multiples in other metrics.

Pro-Dex: Crash After Strong Earnings Leads To A Buying Opportunity

Zacks Investment Research

Pro-Dex, Inc. (PDEX) Q3 Earnings Surpass Estimates

Pro-Dex, Inc. (PDEX) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.47 per share. This compares to earnings of $0.19 per share a year ago.

Pro-Dex, Inc. (PDEX) Q3 Earnings Surpass Estimates

Pro-Dex, Inc. Announces Fiscal 2025 Third Quarter and Nine-Month Results

IRVINE, CA / ACCESS Newswire / May 1, 2025 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2025 third quarter ended March 31, 2025.

Pro-Dex, Inc. Announces Fiscal 2025 Third Quarter and Nine-Month Results

Zacks Investment Research

ProDex (PDEX) Moves 5.1% Higher: Will This Strength Last?

ProDex (PDEX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

ProDex (PDEX) Moves 5.1% Higher: Will This Strength Last?

Zacks Investment Research

Take the Zacks Approach to Beat the Markets: Pro-Dex, Brookdale Senior Living, Coca-Cola in Focus

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Take the Zacks Approach to Beat the Markets: Pro-Dex, Brookdale Senior Living, Coca-Cola in Focus

Zacks Investment Research

ProDex (PDEX) Surges 7.4%: Is This an Indication of Further Gains?

ProDex (PDEX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

ProDex (PDEX) Surges 7.4%: Is This an Indication of Further Gains?

Zacks Investment Research

ProDex (PDEX) Upgraded to Strong Buy: Here's What You Should Know

ProDex (PDEX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ProDex (PDEX) Upgraded to Strong Buy: Here's What You Should Know

Q4 2024 Portfolio Update: Growth Has Come Patiently

In 4Q24, we crossed $10M in AUM, emphasizing patient growth and strategic portfolio management, with a focus on long-term investments and five-year doubles. Key drivers include CCRD, PDEX, and RSSS, with CoreCard benefiting from a new contract with Goldman, and Pro-Dex showing strong business performance. Matrix Service is expected to convert backlog to profit in the next 18-24 months, while new positions are anticipated to start small.

Q4 2024 Portfolio Update: Growth Has Come Patiently

Zacks Investment Research

Pro-Dex, Inc. (PDEX) Surpasses Q2 Earnings and Revenue Estimates

Pro-Dex, Inc. (PDEX) came out with quarterly earnings of $0.61 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.14 per share a year ago.

Pro-Dex, Inc. (PDEX) Surpasses Q2 Earnings and Revenue Estimates

Pro-Dex, Inc. Announces Fiscal 2025 Second Quarter and Six-Month Results

IRVINE, CA / ACCESS Newswire / January 30, 2025 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2025 second quarter ended December 31, 2024.

Pro-Dex, Inc. Announces Fiscal 2025 Second Quarter and Six-Month Results

See News Rankings

Charts implemented using Lightweight Charts™